Spleen size in patients with metabolic syndrome and its relation to metabolic and inflammatory parameters
| Autor: | Laila A. Rashed, Mervat Naguib, Rokaya Abd El-Aziz |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
nonalcoholic fatty liver disease medicine.medical_specialty lcsh:Internal medicine Waist interleukin-10 Gastroenterology metabolic syndrome 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Nonalcoholic fatty liver disease medicine lcsh:RC31-1245 medicine.diagnostic_test Triglyceride business.industry Fatty liver medicine.disease 030104 developmental biology chemistry Alkaline phosphatase 030211 gastroenterology & hepatology spleen Metabolic syndrome Steatosis Lipid profile business |
| Zdroj: | The Egyptian Journal of Internal Medicine, Vol 30, Iss 2, Pp 78-82 (2018) |
| ISSN: | 2090-9098 1110-7782 |
| Popis: | Introduction Spleen may be enlarged in patients with metabolic syndrome (MS). Many factors that are encountered in MS were incriminated as etiology of the splenomegaly. The aim of this study was to assess spleen longitudinal diameter (SLD) in patients with MS and to investigate the possible factors affecting spleen size. Patients and methods The study included 60 patients with MS and 30 healthy controls. Assessment of full medical history, anthropometric measurements, and abdominal ultrasound to identify SLD and hepatic steatosis was carried out. Liver enzymes, lipid profile, and interleukin-10 (IL-10) were measured. Fatty liver index, which is considered a marker of nonalcoholic fatty liver disease, was calculated from serum triglyceride, BMI, waist circumference, and γ-glutamyl transferase. Results SLD was significantly higher in patients with MS than controls (123.57±13.88 vs. 101.20±5.44 mm, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink